歌礼制药-B(01672)早盘高开,股价上涨27.14%,现报6.09港元,成交额5661.38万港元。
歌礼制药宣布,小分子口服GLP-1R激动剂ASC30在美国的Ib期多剂量递增研究取得积极期中结果。在MAD队列2中,经过28天的每日一次服用ASC30口服片,肥胖症患者的体重相对基线平均下降6.3%。而在MAD队列1中,体重相对基线平均下降4.3%。相较之下,服用安慰剂的患者体重相对基线仅下降0.1%。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.